IDOGEN.ST实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (6 Jul 2023 @ 22:26):

Stats
今日成交量	1.13M
平均成交量	0.00
市值	12.79M
EPS	SEK-0.0727 ( 2023-05-09 )
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-0.320
ATR14	SEK0.0520 (43.15%)

音量相关性

長: 0.58 (weak)

短: 0.25 (neutral)

Signal:(48.38) Neutral

Idogen AB (publ) 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Idogen AB (publ) 相关性 - 货币/商品

0.43
( neutral )

0.39
( neutral )

0.00
( neutral )

0.73
( moderate )

-0.21
( neutral )

-0.47
( neutral )

Idogen AB (publ) 财务报表

Annual	2022
营收:	SEK0
毛利润:	SEK0 (0.00 %)
EPS:	SEK-0.760

FY	2022
营收:	SEK0
毛利润:	SEK0 (0.00 %)
EPS:	SEK-0.760

FY	2021
营收:	SEK0.00
毛利润:	SEK0.00 (0.00 %)
EPS:	SEK-1.699

FY	2020
营收:	SEK0.00
毛利润:	SEK0.00 (0.00 %)
EPS:	SEK-3.32

Financial Reports:

No articles found.

Idogen AB (publ)

Idogen AB (publ), a biotechnology company, develops tolerogenic cell therapies to prevent the patient's immune system from attacking biological agents, transplanted organs, and the body's own cells or tissues in Sweden. The company's advanced product candidate is IDO 8 that is designed for patients with severe haemophilia A, who have developed neutralizing antibodies against critical treatment with coagulation factor VIII. It also develops IDO T, a tolerogenic cell therapy to prevent organ transplant rejection primarily kidney transplantation; and IDO AID for the treatment of autoimmune diseases. The company was incorporated in 2008 and is headquartered in Lund, Sweden.